The Stroke Hyperglycemia Insulin Network Effort (SHINE) Trial

Project: Research project

Description

DESCRIPTION (provided by applicant): There is an increasing need for improved treatments for stroke patients as stroke is a common, devastating and extremely costly disease to the health care system. Forty percent of acute ischemic stroke patients are hyperglycemic upon arrival to the hospital. Hyperglycemia is associated with worse clinical outcome but it is unclear if tight glucose control can improve outcome. Severe or prolonged hypoglycemia can also be very damaging to ischemic brain. Clinical equipoise exists and current American Heart Association Guidelines encourage clinical trials to provide evidence on how to treat hyperglycemic acute stroke patients. The SHINE Trial is a multicenter, randomized, single blind (double blind outcomes) Phase III trial of 1400 patients at 56 sites across the United States. Patients will be randomized to IV insulin with tight glucose control (80-130 mg/dL) versus standard sliding scale subcutaneous insulin (
StatusFinished
Effective start/end date8/1/117/31/18

Funding

  • National Institutes of Health: $1,096,776.00
  • National Institutes of Health: $2,212.00
  • National Institutes of Health: $3,936,454.00
  • National Institutes of Health: $4,966,983.00
  • National Institutes of Health: $8,079,901.00
  • National Institutes of Health: $3,524,233.00

Fingerprint

Hyperglycemia
Stroke
Insulin
Glucose
Hypoglycemia
Clinical Trials
Guidelines
Delivery of Health Care
Brain
Therapeutics

ASJC

  • Medicine(all)
  • Neuroscience(all)